Wei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Dechun Geng
Department of Orthopedics, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication Gert Storm
Department of Surgery, Yong Loo Lin School of Medicine
1 shared publication- Jiaxiang Bai
Department of Orthopedics, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, China
1 shared publication Jie Wu
Department of Orthopedics, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou 215006, P.R. China
1 shared publication- Kun Xi
Department of Orthopedics, First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 188 Shizi Road, Suzhou, Jiangsu, 215006, P. R. China
1 shared publication Liang Chen
Department of Orthopedics, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou 215006, P.R. China
1 shared publication
Latest Publications
- Top Cited Papers
- 4 August 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (31) , 28353-28371
An Immunomodulating Regenerating Hydrogel That Rescues the Oxidative Microenvironment and Reverses Cell Senescence for Osteoporotic Bone Defects
Osteoporosis, which is characterized by reduced bone mass and structurally compromised bone tissue, along with aberrant levels of reactive oxygen species (ROS) and inflammation, has been a pressing clinical challenge. A large accumulation of ROS and pro-inflammatory factors can result in mitochondrial dysfunction and progressive cellular senescence, impeding efficacious regeneration of bone defects. Herein, in this work, a ROS-responsive hydrogel system containing HA-PBA coated Ce-ZOL nanocomposites (GHCZ) for excessive ROS scavenging and reversal of cellular senescence to accelerate bone regeneration in osteoporosis was designed and presented. The GHCZ hydrogel system allows for the sustained release of HA-PBA coated Ce-ZOL nanoparticles, which may scavenge the extracellular and intracellular ROS of BMSCs and macrophages through their prominent enzyme-like catalytic effect. Moreover, the GHCZ hydrogel system transforms the polarization phenotype of macrophages into anti-inflammation M2 type and inhibits pro-inflammatory cytokines. Meanwhile, it could reverse the senescence of BMSCs and apparently elevate their pro-osteogenic capacity through safeguarding mitochondrial function and reprograming the metabolic processes, ultimately promoting the healing of bone defects. Based on in vitro and in vivo results, powerful immunomodulation, favorable pro-inflammatory/oxidative microenvironment reshaping properties, desirable mitochondrial protection, and superior pro-osteogenic capacity of such a GHCZ hydrogel system display the profound effects on augmenting bone repair, which offers a paradigm for treating osteoporotic bone defects.
- 4 August 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (31) , 28353-28371
Top Cited PapersAn Immunomodulating Regenerating Hydrogel That Rescues the Oxidative Microenvironment and Reverses Cell Senescence for Osteoporotic Bone Defects
Osteoporosis, which is characterized by reduced bone mass and structurally compromised bone tissue, along with aberrant levels of reactive oxygen species (ROS) and inflammation, has been a pressing clinical challenge. A large accumulation of ROS and pro-inflammatory factors can result in mitochondrial dysfunction and progressive cellular senescence, impeding efficacious regeneration of bone defects. Herein, in this work, a ROS-responsive hydrogel system containing HA-PBA coated Ce-ZOL nanocomposites (GHCZ) for excessive ROS scavenging and reversal of cellular senescence to accelerate bone regeneration in osteoporosis was designed and presented. The GHCZ hydrogel system allows for the sustained release of HA-PBA coated Ce-ZOL nanoparticles, which may scavenge the extracellular and intracellular ROS of BMSCs and macrophages through their prominent enzyme-like catalytic effect. Moreover, the GHCZ hydrogel system transforms the polarization phenotype of macrophages into anti-inflammation M2 type and inhibits pro-inflammatory cytokines. Meanwhile, it could reverse the senescence of BMSCs and apparently elevate their pro-osteogenic capacity through safeguarding mitochondrial function and reprograming the metabolic processes, ultimately promoting the healing of bone defects. Based on in vitro and in vivo results, powerful immunomodulation, favorable pro-inflammatory/oxidative microenvironment reshaping properties, desirable mitochondrial protection, and superior pro-osteogenic capacity of such a GHCZ hydrogel system display the profound effects on augmenting bone repair, which offers a paradigm for treating osteoporotic bone defects.
- Open Access
- 30 July 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3112388
Emerging Potential Therapeutic Targets of Ferroptosis in Skeletal Diseases
Ferroptosis is a new programmed cell death characterized by the accumulation of lipid peroxidation mediated by iron and inflammation. Since the transcentury realization of ferroptosis as an iron‐dependent modality of nonapoptotic cell death in 2012, there has been growing interest in the function of ferroptosis and its relationship to clinical diseases. Recent studies have shown that ferroptosis is associated with multiple diseases, including degenerative diseases, ischemia reperfusion injury, cardiovascular disease, and cancer. Cell death induced by ferroptosis has also been related to several skeletal diseases, such as inflammatory arthritis, osteoporosis, and osteoarthritis. Research on ferroptosis can clarify the pathogenesis of skeletal diseases and provide a novel therapeutic target for its treatment. In this review, we summarize current information about the molecular mechanism of ferroptosis and describe its emerging role and therapeutic potential in skeletal diseases.
- 30 July 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3112388
Open AccessEmerging Potential Therapeutic Targets of Ferroptosis in Skeletal Diseases
Ferroptosis is a new programmed cell death characterized by the accumulation of lipid peroxidation mediated by iron and inflammation. Since the transcentury realization of ferroptosis as an iron‐dependent modality of nonapoptotic cell death in 2012, there has been growing interest in the function of ferroptosis and its relationship to clinical diseases. Recent studies have shown that ferroptosis is associated with multiple diseases, including degenerative diseases, ischemia reperfusion injury, cardiovascular disease, and cancer. Cell death induced by ferroptosis has also been related to several skeletal diseases, such as inflammatory arthritis, osteoporosis, and osteoarthritis. Research on ferroptosis can clarify the pathogenesis of skeletal diseases and provide a novel therapeutic target for its treatment. In this review, we summarize current information about the molecular mechanism of ferroptosis and describe its emerging role and therapeutic potential in skeletal diseases.